Treatment
Pemetrexed clinical trials
We’re tracking 167 recruiting studies that include Pemetrexed, each written for real people, not researchers, below.
Recruiting studies
- NCT06399926Recruiting
Pemetrexed via Ommaya for lung cancer in brain lining
This study tests whether a drug called pemetrexed, given directly into the fluid around your brain through a small implanted device, is safe and effective for treating lung cancer that has spread to the lining of the brain. It is for people whose cancer has a specific genetic change (EGFR, ALK, or ROS1) and who have already tried standard targeted pills that no longer control their disease.
Changsha, HunanAges 18 years+ - NCT07061379Recruiting
Patient feedback in first-line lung cancer treatment study
This study collects patient feedback through questionnaires to see if it helps improve outcomes for people with advanced non-small-cell lung cancer starting chemo-immunotherapy. It may help your care team better understand how you are feeling.
Milan, ItalyAges 18 years+ - NCT05431270RecruitingPhase 1/Phase 2
Test drug that targets CD73, alone or with immunotherapy
This early-stage study tests mavrostobart (an anti-CD73 antibody) to see what dose is safe and whether it can help shrink tumors. It’s studied by itself and also with a PD-1 immune therapy or chemotherapy, depending on your cancer type and prior treatments.
Huntersville, North CarolinaAges 18 years+ - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT05055908RecruitingPhase 3
Testing immune-therapy for lung cancer and predicting response
This trial studies how well immune checkpoint medicines (with or without chemotherapy) work for lung cancer, and looks for biomarkers—tests that may help predict who benefits. It may help you access a structured treatment plan and additional response testing.
Changsha, HunanAges 18 years+ - NCT06543069RecruitingPhase 2
Combination therapy for unresectable peritoneal mesothelioma
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
BeijingAges 18 years+ - NCT07777822RecruitingPhase 3
First-line treatment for metastatic non-squamous lung cancer with RAS mutation
This trial tests whether adding a new drug (zoldonrasib) to standard chemotherapy and immunotherapy can help people with a specific type of lung cancer. It is for those with a RAS G12D mutation and no prior treatment for metastatic disease.
Plantation, FloridaAges 18 years+ - NCT07744529RecruitingPhase 1/Phase 2
Combination treatment for lung cancer spread to the lining of the brain
This trial tests a new combination of two drugs for people with a specific type of lung cancer that has spread to the lining of the brain and spinal cord. The treatment aims to target the cancer cells and may help improve symptoms and survival.
Hangzhou, ZhejiangAges 18 years+ - NCT07594626RecruitingPhase 1/Phase 2
BMS-986504 and Pemetrexed for Advanced Tumors With MTAP Loss
This trial tests a new drug (BMS-986504) combined with an existing chemotherapy (pemetrexed) for advanced solid cancers that have a specific genetic change called MTAP deletion. The trial aims to see if this combination can slow or stop tumor growth in patients whose cancer has progressed despite prior treatment.
Chicago, IllinoisAges 18 years+ - NCT06794645RecruitingPhase 2
Pembrolizumab and Pemetrexed for Growing Chordoma
This trial tests two drugs—pembrolizumab (Keytruda) and pemetrexed—for people with chordoma that has continued to grow. The goal is to see if the combination can slow or stop the tumor. You'll need to be in fairly good health and able to take other medicines (folic acid and vitamin B12) to protect your body from side effects.
Santa Monica, CaliforniaAges 18 years+ - NCT07397338RecruitingPhase 1/Phase 2
RAS inhibitors with ivonescimab for solid tumors
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06901817RecruitingPhase 2
Study of pemetrexed plus nivolumab for lung cancer that has spread to the lining of the brain
This trial tests a combination of two drugs, pemetrexed and nivolumab, given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (non-squamous non-small cell) that has spread to the lining of the brain and has not responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05209620RecruitingPhase 2
Orelabrutinib plus pemetrexed for lymphoma in the brain
This Phase 2 trial tests a combination medicine (orelabrutinib with pemetrexed) to treat lymphoma that has returned or is not responding, specifically in the brain or spinal fluid. If you qualify, the goal is to shrink measurable tumors and improve control of central nervous system lymphoma.
Zhengzhou, HenanAges 18–75 - NCT07100080RecruitingPhase 2/Phase 3
New drug vs chemotherapy for EGFR-mutated lung cancer
This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.
Irvine, CaliforniaAges 18 years+ - NCT06809517RecruitingPhase 1/Phase 2
Study of a new antibody plus chemotherapy for leptomeningeal metastasis
This trial tests a combination treatment for cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). It uses an antibody given directly into the spinal fluid along with a chemotherapy drug, with the goal of targeting the cancer more effectively.
Huizhou, GuangdongAges 21–75 - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Anchorage, AlaskaAges 18 years+ - NCT04136535RecruitingPhase 2
Treating resistant lung cancer with chemo plus or minus an added drug
This Phase 2 study tests whether adding an extra targeted medicine (anlotinib) to standard chemotherapy (pemetrexed and carboplatin) can better control osimertinib-resistant lung cancer with an EGFR mutation. It’s for people whose lung cancer has already progressed after osimertinib, and it aims to shrink tumors and slow the disease.
Shenzhen, shenzhenAges 18–75 - NCT06663306RecruitingPhase 1
Intrathecal pemetrexed and bevacizumab for lung cancer brain spread
This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.
ShanghaiAges 18 years+ - NCT06630416RecruitingPhase 2
Pemetrexed for advanced bladder and other cancers with certain gene changes
This trial tests if a chemotherapy drug called pemetrexed works better in advanced bladder cancer or other solid tumors that have specific genetic changes (MLL4, UTX, or MTAP). It is for people who have already tried at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT06296745RecruitingPhase 2
Pemetrexed in spinal fluid for lung cancer that spread to brain lining
This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.
Huizhou, GuangdongAges 18–75 - NCT06304441Recruiting
Pemetrexed plus lung cancer pill for brain metastasis
This trial tests if adding an injected chemotherapy drug (pemetrexed) to a targeted oral pill (like osimertinib) works better than the pill alone for patients with lung cancer that has spread to the brain and spinal cord lining.
Huizhou, GuangdongAges 18–75 - NCT05805631RecruitingPhase 2
Pemetrexed into spinal fluid for EGFR-mutant lung cancer spread to brain lining
This Phase 2 trial tests giving pemetrexed directly into the spinal fluid to treat cancer that has spread to the brain’s and spinal cord’s lining (leptomeningeal metastasis). It is for people with EGFR-mutant non-squamous lung cancer whose disease progressed after osimertinib, and who may benefit from a targeted treatment delivered to the area affected in the brain lining.
Taipei, TaiwanAges 20 years+ - NCT05681195RecruitingPhase 2
Zanubrutinib plus pemetrexed for recurrent brain lymphomas
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
Miami, FloridaAges 18 years+ - NCT05456256RecruitingPhase 2
LP-300 plus chemo for lung cancer in never-smokers
This Phase 2 trial tests LP-300 with carboplatin and pemetrexed to treat advanced lung adenocarcinoma in people who have never smoked. It may help shrink tumors and slow the disease in a specific genetic group of lung cancer.
Beverly Hills, CaliforniaAges 18 years+
What Pemetrexed is being studied for
Conditions with recruiting Pemetrexed studies.
Common questions
- Are there clinical trials studying Pemetrexed?
- Yes. Clin2 currently lists 167 recruiting studies that include Pemetrexed, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Pemetrexed trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Pemetrexed an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Pemetrexed or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.